The major player in India’s agrochemical and specialty chemical space, Safex Chemicals (India), has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI). The company, known for its presence across branded formulations, specialty chemicals, and contract development and manufacturing organization (CDMO) segments, is poised to make a significant impact with its Initial Public Offering (IPO) in the rapidly growing Indian and global agrochemical ecosystem.
The IPO comprises a fresh issue of up to INR 450 crore and an Offer for Sale (OFS) of up to 35.73 million equity shares. Key promoter shareholders, including Surinder Kumar Chaudhary, Rajesh Kumar Jindal, Neeraj Kumar Jindal, and Piyush Jindal, along with investor entities such as Sarcoline (backed by ChrysCapital), Anchor Partners, and Sage Investment Trust, will be selling part of their holdings through the OFS. Notably, ChrysCapital-backed Sarcoline is the largest shareholder with 42.20% of pre-offer equity.
Business Model: Diversified and Synergistic
Safex Chemicals operates a multi-vertical model that spans across several key areas:
- Branded Formulations: The company offers over 140 products, including insecticides, herbicides, fungicides, fertilizers, and plant growth regulators (PGRs) through its flagship brands: Safex, Indo Swiss, and Smith n Smith. It boasts a pan-India direct distribution network of more than 14,950 active dealers, eliminating intermediaries to improve margins and customer touchpoints.
- Specialty Chemicals: Through its wholly-owned subsidiary, Shogun Organics, Safex manufactures agrochemical active ingredients and household insecticides. Notably, it developed and patented Renofluthrin, India’s first indigenous mosquito repellent molecule, and has a supply agreement with Godrej Consumer Products.
- CDMO Business: Through Briar Chemicals in the UK, acquired in 2022, Safex provides custom synthesis and formulation services to major agrochemical players including Bayer AG, with a long-term contract.
This comprehensive presence across the agrochemical value chain allows for internal synergies, backward integration, margin enhancement, and supply chain optimization.
Financial Performance and IPO Details
Safex’s revenue from operations grew at a CAGR of approximately 17% from FY23 to FY25, reaching INR 1,584.78 crore in FY25, compared to INR 1,161.02 crore in FY23. The revenue breakdown for FY25 was:
- Branded Formulations: INR 989.99 crore
- Specialty Chemicals: INR 274.15 crore
- CDMO: INR 428.11 crore
However, the company reported a net loss of INR 14.29 crore in FY25, despite an EBITDA of INR 233.03 crore and an EBITDA margin of 14.7%, due to exceptional items and tax costs. Return ratios are under pressure, with ROE at -2.12% and ROCE at 10.65%. On the balance sheet front, the company has a net debt-to-equity ratio of 0.95x, indicating a leveraged but manageable capital structure. The IPO proceeds will be used to repay borrowings of INR 365.58 crore, including subsidiary-level debt.
Operational Footprint and Sector Tailwinds
Safex operates eight manufacturing facilities: six in India (for branded formulations), one in Pune (specialty chemicals), and one in Norwich, UK (CDMO). As of FY25, capacity utilization was:
- Powder formulations: 78.81%
- Granules and liquids: 56.62% and 15.58% respectively
- Specialty chemicals: 19.98% utilization
- CDMO: 29.38% utilization
The company is expanding its “Golden Farms” ag-tech platform to connect farmers, dealers, and agri-experts. With 17,413 dealers already onboarded, it aims to digitize engagement and promote product discovery and analytics-led insights.
India’s specialty chemicals market, valued at USD 89 billion in FY24, is expected to reach USD 145 billion by FY30, growing at an 8.5% CAGR. This growth is driven by global supply chain diversification away from China and increasing demand across agrochemicals, home care, and pharma sectors. Agrochemicals specifically are expected to touch USD 33.4 billion by FY30, forming 23% of India’s specialty chemical market.
Investment Highlights and Challenges
Safex Chemicals presents several investment highlights:
- Presence across the value chain: A backward integrated model across formulation, specialty chemicals, and CDMO.
- Geographic diversification: Operations in 22 countries across six continents.
- Strong promoter and institutional backing: ChrysCapital owns a 44.80% stake.
- Innovation-led: Six patents, 17 R&D scientists, and INR 182.7 crore revenue from new products in FY25.
- Digital and direct: A direct-to-dealer model with digital integration for real-time dealer support and analytics.
Nevertheless, the company faces challenges such as unstable profitability despite a strong topline, high working capital intensity due to an inventory-heavy formulation business, and customer concentration risks, with dependence on key customers like Godrej and Bayer. Additionally, underutilized capacities in CDMO and specialty chemicals may limit operating leverage in the near term.
With a strong platform across the agrochemical value chain, backed by strategic acquisitions and a multi-brand strategy, Safex Chemicals is ready to capitalize on growth opportunities in India’s agriculture and global specialty chemical markets. The IPO is a significant step in Safex’s journey from an agrochemical company to a diversified, innovation-led, multinational chemical company.
For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription, stay tuned to IPO Central.
